Industry News
Excerpt from the Press Release: PRINCETON, NJ / ACCESSWIRE / January 19, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that pharmacokinetic (PK) profile simulation of SON-1010 dosing has been completed in its randomized, placebo-controlled Phase 1 clinical trial in healthy volunteers. Historically,…
Read More
Compass to Host Investor Event on Monday, January 23rd at 8:30am ET Excerpt from the Press Release: BOSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the presentation of data from a Phase 2 study of…
Read More
IND demonstrates Mirati’s leadership in KRAS, representing the Company’s third KRAS or KRAS-signaling program to enter clinical development Excerpt from the Press Release: SAN DIEGO, Jan. 19, 2023 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of MRTX1133, a potential…
Read More
Excerpt from the Press Release: SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ — Vial, a global tech-enabled CRO providing next-generation clinical trial management services, announced that the first patient has been enrolled in the clinical trial TLL018-205, a Phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of TLL-018 in human subjects with moderate…
Read More
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Dose escalation has been completed and enrollment at second dose level will be expanded at Columbia University ADXS-504 has been well tolerated with no serious adverse events reportedFour out of six patients treated are still on study and PSA values are being followed up Excerpt from the Press Release: MONMOUTH JUNCTION, N.J., Jan. 12, 2023…
Read More
Excerpt from the Press Release: CHARLESTOWN, Mass. and NAARDEN, The Netherlands, Jan. 11, 2023 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, and Phlox Therapeutics, a biotech company pioneering a novel approach to gene therapies to alleviate and cure cardiomyopathies, today announced a…
Read More
Collaborative lab space enables development and growth of the next generation of life science companies in the greater Gainesville region Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–As part of its efforts to support emerging biotechnology companies with addressing key challenges of bringing new therapies to market, Thermo Fisher Scientific today announced it has become…
Read More
Meet with Christopher Kata, Director of Sales & Marketing February 6th – 9th, 2023 at the SCOPE Summit for Clinical Operations Executives in Orlando, Florida. Christopher and the TrialStat team are exhibiting in booth # 906. Christopher Kata, Director of Sales & Marketing905 [email protected] Event: SCOPE – Summit for Clinical Operations Executives When: February 6th…
Read More
Three abstracts highlight the safety and efficacy of briquilimab combined with low-toxicity radiation conditioning to achieve full donor engraftment and leukemia disease eradication Excerpt from the Press Release: REDWOOD CITY, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a biotechnology company developing novel antibody therapies addressing chronic…
Read More
Excerpt from the Press Release: OAKLAND, Calif., Jan. 4, 2023 /PRNewswire/ — Tempero Bio, Inc, a clinical-stage biopharmaceutical company focused on developing transformative therapies for the treatment and prevention of alcohol and other substance use disorders, today announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for TMP-301.…
Read More